Semmelweis Uni partnering with AstraZeneca
Image by Marc Bruxelle / Shutterstock.com
Semmelweis University, Hungary's top medical school, and the Hungarian unit of AstraZeneca signed a strategic partnership agreement, the British-Swedish pharmaceutical company said yesterday, according to portfolio.hu.
The deal concerns the extension of joint research and development activity, common programs for treating and diagnosing patients, and studies of diseases such as diabetes, chronic kidney disease, and cardiac failure.
AstraZeneca has already cooperated with the university in almost two-thirds of its clinical trials but the percentage could exceed 80% due to the new partnership, the parties said.
Béla Merkely, the university's rector, said the results of the joint work are expected to be utilized in patient care.
AstraZeneca spends HUF 2 billion a year on R&D activity in Hungary. AstraZeneca Kereskedelmi és Szolgáltató had revenue of more than HUF 15 bln in 2020, including export sales of HUF 2.5 bln.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.